A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission

Table 2 Day 7 piperaquine concentrations by adherence status

	Median drug concentration ng/ml [IQR]	p value¹
Observed intake control group (N = 94)²	128.5 [53.5–189.0]	Reference
Non-observed treatment intake (N = 236)³	95.5 [34.9–186.0]	0.051
Self-reported adherence
Full adherence (N = 215)	107.0 [41.0–192.0]	0.187
Non-adherence (N = 21)	30.4 [2.9–69.6]	< 0.001
Self-reported non-adherence
Completed two doses (N = 8)	57.8 [3.3–100.7]	0.034
Completed one dose (N = 11)	36.8 [2.9–60.9]	0.001
Completed no doses (N = 2)	7.1 [<LLOQ–12.9]	0.017

¹Calculated by the two-sample Wilcoxon rank-sum (Mann-Whitney) test against the observed intake control group. Significant p values are set in italics
²Ten samples with drug concentration falling below the limit of quantification (<LLOQ), three samples with reports of vomiting within 30 min after drug intake, and one sample with self-reported non-adherence were excluded from the control group
³Three samples excluded due to improper sample conditions

ISSN: 1741-7015